| Cesar M Plazas-guzman, MD | |
|
713 Volvo Pkwy Ste 100, Chesapeake, VA 23320-1614 | |
| (757) 609-3404 | |
| (757) 410-7215 |
| Full Name | Cesar M Plazas-guzman |
|---|---|
| Gender | Male |
| Speciality | Endocrinology |
| Experience | 10 Years |
| Location | 713 Volvo Pkwy Ste 100, Chesapeake, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720407851 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chesapeake Regional Medical Center | Chesapeake, VA | Hospital |
| Sentara Leigh Hospital | Norfolk, VA | Hospital |
| The Outer Banks Hospital, Inc | Nags head, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bayview Physician Services Pc | 5597664201 | 307 |
News Archive
Athletes are always on the lookout for new ways to push the limits of human performance and one needs to first pinpoint their current limits objectively if they seek to overcome them.
Senate Majority Leader Harry Reid, D-Nev., made two major changes to the Senate's version of the health overhaul legislation - removing the proposed "public option" and restricting abortion coverage - that have helped ease tension enough to secure more votes for the bill, but left advocates with much to complain about.
NeuroMetrix, Inc., a science-based health care company transforming patient care through neurotechnology, today reported business and financial highlights for the quarter and year ended December 31, 2010.
Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that it has initiated a randomized Phase 1b/2 clinical trial evaluating IPI-926, its novel, oral Hedgehog pathway inhibitor, in combination with gemcitabine in patients with pancreatic cancer.
› Verified 3 days ago
| Entity Name | Bayview Physician Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508813387 PECOS PAC ID: 5597664201 Enrollment ID: O20031231000719 |
News Archive
Athletes are always on the lookout for new ways to push the limits of human performance and one needs to first pinpoint their current limits objectively if they seek to overcome them.
Senate Majority Leader Harry Reid, D-Nev., made two major changes to the Senate's version of the health overhaul legislation - removing the proposed "public option" and restricting abortion coverage - that have helped ease tension enough to secure more votes for the bill, but left advocates with much to complain about.
NeuroMetrix, Inc., a science-based health care company transforming patient care through neurotechnology, today reported business and financial highlights for the quarter and year ended December 31, 2010.
Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that it has initiated a randomized Phase 1b/2 clinical trial evaluating IPI-926, its novel, oral Hedgehog pathway inhibitor, in combination with gemcitabine in patients with pancreatic cancer.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Cesar M Plazas-guzman, MD Po Box 7068, Portsmouth, VA 23707-0068 Ph: (757) 609-3404 | Cesar M Plazas-guzman, MD 713 Volvo Pkwy Ste 100, Chesapeake, VA 23320-1614 Ph: (757) 609-3404 |
News Archive
Athletes are always on the lookout for new ways to push the limits of human performance and one needs to first pinpoint their current limits objectively if they seek to overcome them.
Senate Majority Leader Harry Reid, D-Nev., made two major changes to the Senate's version of the health overhaul legislation - removing the proposed "public option" and restricting abortion coverage - that have helped ease tension enough to secure more votes for the bill, but left advocates with much to complain about.
NeuroMetrix, Inc., a science-based health care company transforming patient care through neurotechnology, today reported business and financial highlights for the quarter and year ended December 31, 2010.
Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that it has initiated a randomized Phase 1b/2 clinical trial evaluating IPI-926, its novel, oral Hedgehog pathway inhibitor, in combination with gemcitabine in patients with pancreatic cancer.
› Verified 3 days ago
Barbara Sarris, Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 4041 Taylor Rd, Suite G, Chesapeake, VA 23321 Phone: 757-484-5828 Fax: 757-484-4371 | |
Dr. Jieming Yan, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 736 Battlefield Blvd N, Chesapeake, VA 23320 Phone: 757-967-8622 Fax: 757-686-0541 | |
Louis Nicondro Carideo, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 808 S Battlefield Blvd, Chesapeake, VA 23322 Phone: 757-482-4721 Fax: 757-546-9108 | |
Himanshu D. Desai, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 710 Liberty St, Chesapeake, VA 23324 Phone: 757-312-8121 | |
Paul J Pontier, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 713 Volvo Pkwy, Ste 100, Chesapeake, VA 23320 Phone: 757-548-0076 Fax: 757-548-1652 | |
Alan J. Gamsey, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 112 Gainsborough Sq, Suite 200, Chesapeake, VA 23320 Phone: 757-547-0798 Fax: 757-547-0145 | |
Dr. David Howell Lasseter, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 713 Volvo Pkwy Ste 101, Chesapeake, VA 23320 Phone: 757-609-3404 Fax: 757-410-7215 |